- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT01470534
Mechanisms Underlying Postoperative Insulin Resistance and Inflammation
Investigating Whether the Magnitude of Postoperative Inflammatory and Insulin Resistant Responses is Related to Body Composition and Physiological Function of Skeletal Muscle & Adipose Tissue
Having an operation places an enormous burden on the body, leading to the development of inflammation and so called 'insulin resistance'. Insulin resistance means the body is unable to respond to important hormones that control use of energy. Recent studies have shown that patients who develop 'higher' insulin resistance and inflammation have more serious complications and take longer to recover after surgery. The investigators do not know what controls the development of insulin resistance and inflammation after surgery. Similarly, the investigators do not know why certain patients develop much more insulin resistance and inflammation than others, even though they have the same operation.
The main purpose of the study is to try to find out which patients are prone to developing greater 'amounts' of insulin resistance and inflammation. The investigators also want to find out whether the investigators can reduce the 'amount' of insulin resistance and inflammation in these patients (for example by giving them carbohydrate [sugar-based] drinks before surgery - these have been shown to reduce insulin resistance in some patient groups).
Information from this study should improve the way the investigators prepare patients before surgery and this should help to improve patient outcomes following surgery (by reducing complications and speeding recovery after major surgery).
Aperçu de l'étude
Statut
Les conditions
Description détaillée
Interested participants who are undergoing abdominal (tummy) surgery will be recruited from surgical clinics. They will be asked to attend the Greenfield Human Physiology Laboratory where they will be asked to complete two questionnaires. In addition, a sample of blood, and a small sample of muscle and fat from their thigh will be taken. They will undergo a low dose X-ray (DXA scan) and an insulin clamp. The insulin clamp involves being connected to an insulin and glucose drip for around four hours during which their blood pressure and pulse is monitored and regular blood samples are taken.
Participants will be allocated randomly to one of two groups. One group will receive a carbohydrate (sugar) drink before surgery and the other group will receive a dummy (placebo) drink.
On the day of surgery, pre-operative checks and assessment will proceed as normal. After the participant is asleep under anaesthetic, a blood sample and tummy muscle and fat samples will be taken by the surgeon through the surgical incision. At the end of surgery, another blood sample and muscle and fat samples from the tummy and thigh will be taken while the participant is still under anaesthetic.
On the day after surgery, a further blood test and tummy and thigh muscle and fat sample will be taken. Participants will also undergo another insulin clamp.
The research team will follow participants' progress after surgery, but the decision to allow them home will be made by the medical team responsible for their care.
Type d'étude
Inscription (Anticipé)
Phase
- Phase 4
Contacts et emplacements
Lieux d'étude
-
-
-
Nottingham, Royaume-Uni, NG7 2UH
- Recrutement
- University of Nottingham
-
Contact:
- Dileep Lobo
- E-mail: dileep.lobo@nottingham.ac.uk
-
Chercheur principal:
- Dileep Lodo
-
-
Critères de participation
Critère d'éligibilité
Âges éligibles pour étudier
Accepte les volontaires sains
Sexes éligibles pour l'étude
La description
Inclusion Criteria:
- Age 18-75 yrs
- Correct BMI and waist circumference criteria : Obese group - BMI ≥30 AND waist circumference ≥94 cm in men and ≥ 80 cm in women, Non obese group - BMI 18.5-25 AND waist circumference ≤94cm in men and ≤80 cm in women Due to undergo elective major abdominal surgery ASA I-III Caucasian patients Able to give informed consent and comply with study protocol
Exclusion Criteria:
History of significant preoperative weight loss (>10% over preceding 3 weeks)
- Clinical history of pulmonary aspiration
- Known gastro-oesophageal reflux disease (GORD) or hiatus hernia
- History of difficult intubation or conditions leading to the latter such as: previous neck radiotherapy/rheumatoid arthritis/presence of thyroid goitre
- Metabolic disorders (e.g. diabetes mellitus, thyroid disease, Cushing's Syndrome)
- Simultaneous participation in another clinical study or involvement in a clinical study within the preceding 3 months,
- Patients with suspicion of alcohol/drug abuse
- Pregnancy
Plan d'étude
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Science basique
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Double
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Obèse
|
carbohydrate drink
Open muscle biopsy
Venopuncture
|
Expérimental: Normal body weight
|
carbohydrate drink
Open muscle biopsy
Venopuncture
|
Comparateur placebo: Normal Body Weight placebo
Participants of mormal body weight given placebo
|
Open muscle biopsy
Venopuncture
|
Comparateur placebo: Obese placebo
Participants who are obese given placebo
|
Open muscle biopsy
Venopuncture
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
Within subject differences in perioperative insulin sensitivity (M-value, corrected for insulin concentrations) amongst obese, non-obese, carbohydrate loaded and non-carbohydrate loaded patients.
Délai: 2 weeks
|
2 weeks
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Correlation between body composition and changes in perioperative insulin sensitivity
Délai: 2 weeks
|
2 weeks
|
Differences in inflammatory cytokine gene expression
Délai: 2 months
|
2 months
|
Differences in muscle and fat genes and proteins controlling carbohydrate/fat oxidation and insulin signalling
Délai: 3 months
|
3 months
|
Differences activities of muscle and fat enzymes involved in carbohydrate/fat/carnitine metabolism
Délai: 2 months
|
2 months
|
Differences in the aforementioned between peripheral and central fat and muscle
Délai: 2 months
|
2 months
|
The incidence of post-operative infectious and non-infectious complications
Délai: 30 days
|
30 days
|
Length of hospital stay (difference between groups)
Délai: 6 weeks
|
6 weeks
|
Collaborateurs et enquêteurs
Parrainer
Dates d'enregistrement des études
Dates principales de l'étude
Début de l'étude
Achèvement primaire (Anticipé)
Achèvement de l'étude (Anticipé)
Dates d'inscription aux études
Première soumission
Première soumission répondant aux critères de contrôle qualité
Première publication (Estimation)
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
Dernière mise à jour soumise répondant aux critères de contrôle qualité
Dernière vérification
Plus d'information
Termes liés à cette étude
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- 11040 (DAIDS ES Registry Number)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Placebo
-
SamA Pharmaceutical Co., LtdInconnueBronchite aiguë | Infection aiguë des voies respiratoires supérieuresCorée, République de
-
National Institute on Drug Abuse (NIDA)ComplétéConsommation de cannabisÉtats-Unis
-
Heptares Therapeutics LimitedComplétéPharmacocinétique | Des problèmes de sécuritéRoyaume-Uni
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyComplétéSujets masculins atteints de diabète de type II (T2DM)Allemagne
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingComplétéMaladie de ParkinsonChine
-
ItalfarmacoComplétéDystrophie musculaire de BeckerPays-Bas, Italie
-
Guangdong Zhongsheng Pharmaceutical Co., Ltd.Complété
-
West Penn Allegheny Health SystemComplétéAsthme | Rhinite allergiqueÉtats-Unis
-
Regado Biosciences, Inc.ComplétéVolontaire en bonne santéÉtats-Unis